Risk of cardiovascular disease associated with use of tumor necrosis factor inhibitors in ankylosing spondylitis
In a real-world AS cohort, TNFi treatment was associated with a reduced risk of atherosclerotic CVD. However, TNFi use was not associated with risk of congestive heart failure.
Authors
- Jun Sik Yoon (ORCID: https://orcid.org/0000-0003-4328-3955)
- Sojeong Park (ORCID: https://orcid.org/0000-0001-6019-6912)
- Hasung Kim (ORCID: https://orcid.org/0000-0002-2519-6244)
- Bo Young Kim
- Jung‐Yoon Choe (ORCID: https://orcid.org/0000-0003-0957-0395)
- Hwajeong Lee (ORCID: https://orcid.org/0000-0002-1592-7314)
- Seong‐Kyu Kim (ORCID: https://orcid.org/0000-0002-7780-0167)
- Sung‐Hoon Park (ORCID: https://orcid.org/0000-0002-3218-5420)
- JW Kim (ORCID: https://orcid.org/0000-0002-0498-5762)
Institutions
- Daegu Catholic University (KR)
- Hanmi Pharmaceutical (South Korea) (KR)
- Inje University Busan Paik Hospital (KR)
Publication Details
- Journal
- Journal of Rheumatic Diseases
- Published
- 2025-08-26
- DOI
- https://doi.org/10.4078/jrd.2025.0070
- Primary Topic
- Spondyloarthritis Studies and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Research Foundation
- National Research Foundation of Korea
- Ministry of Science and ICT, South Korea